Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZBCCA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
mGC028
|
|||||
| Synonyms |
MGC028
Click to Show/Hide
|
|||||
| Organization |
MacroGenics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-ADAM9 antibody
|
Antibody Info | ||||
| Antigen Name |
Disintegrin and metalloproteinase domain-containing protein 9 (ADAM9)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Bicyclononyne carbamoyl sulfamide Val-Ala-PABC
|
Linker Info | ||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Biliary tract cancer |
1 Trials
|
||||||||
| Colorectal cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Pancreatic cancer |
1 Trials
|